Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRI.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
9
11
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
ppublish
Résumé
To evaluate a correlation between an MRI-specific marker for cellular density [apparent diffusion coefficient (ADC)] and the expression of Somatostatin Receptors (SSTR) in patients with meningioma of the skull plane and orbital space. 68 Ga-DOTATOC PET/MR imaging was performed in 60 Patients with suspected or diagnosed meningiomas of the skull base and eye socket. Analysis of ADC values succeeded in 32 patients. ADC values (ADC mean and ADC min ) were analyzed using a polygonal region of interest. Tracer-uptake of target lesions was assessed according to corresponding maximal (SUV max ) and mean (SUV mean ) values. Correlations between assessed parameters were evaluated using the Pearson correlation coefficient. One out of 32 patients (3%) was diagnosed with lymphoma by histopathological examination and therefore excluded from further analysis. Median ADC mean amounted to 822 × 10 -5 mm²/s -1 (95% CI: 570-1497) and median ADC min was 493 × 10 -5 mm 2 /s -1 (95% CI: 162-783). There were no significant correlations between SUV max and ADC min (r = 0.60; P = 0.76) or ADC mean (r = -0.52; P = 0.79), respectively. However, Pearson's test showed a weak, inverse but insignificant correlation between ADC mean and SUV mean (r = -0.33; P = 0.07). The presented data displays no relevant correlations between increased SSTR expression and cellularity in patients with meningioma of the skull base. SSTR-PET and DWI thus may offer complementary information on tumor characteristics of meningioma.
Identifiants
pubmed: 37823259
doi: 10.1097/MNM.0000000000001774
pii: 00006231-990000000-00221
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Edotreotide
U194AS08HZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1106-1113Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, et al. Meningioma. Crit Rev Oncol Hematol 2008; 67:153–171.
Krampla W, Newrkla S, Pfisterer W, Jungwirth S, Fischer P, Leitha T, et al. Frequency and risk factors for meningioma in clinically healthy 75-year-old patients: results of the transdanube ageing study (VITA). Cancer 2004; 100:1208–1212.
Nassiri F, Zadeh G. How should we manage incidental meningiomas? Neuro Oncol 2020; 22:173–174.
Yan P-F, Yan L, Hu T-T, Xiao D-D, Zhang Z, Zhao H-Y, et al. The potential value of preoperative MRI texture and shape analysis in grading meningiomas: a preliminary investigation. Transl Oncol 2017; 10:570–577.
Preusser M, Silvani A, Le Rhun E, Soffietti R, Lombardi G, Sepulveda JM, et al. . Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro Oncol 2022; 24:755–767.
Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, et al. TERT promoter mutations and risk of recurrence in meningioma. JNCI 2016; 108:djv377.
Najafabadi AHZ, van der Meer PB, Boele FW, Taphoorn MJ, Klein M, Peerdeman SM, et al. Long-term disease burden and survivorship issues after surgery and radiotherapy of intracranial meningioma patients. Neurosurgery 2021; 88:155.
Haubold J, Demircioglu A, Gratz M, Glas M, Wrede K, Sure U, et al. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting. EJNMMI 2020; 47:1435–1445.
Haubold J, Hosch R, Parmar V, Glas M, Guberina N, Catalano OA, et al. Fully automated MR based virtual biopsy of cerebral gliomas. Cancers (Basel) 2021; 13:6186.
Li Z, Kaiser L, Holzgreve A, Ruf VC, Suchorska B, Wenter V, et al. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F] FET PET radiomics. EJNMMI 2021; 48:4415–4425.
Qiao XJ, Kim HG, Wang DJ, Salamon N, Linetsky M, Sepahdari A, et al. Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas. EJR 2017; 97:31–36.
Hu J, Zhao Y, Li M, Liu J, Wang F, Weng Q, et al. Machine learning-based radiomics analysis in predicting the meningioma grade using multiparametric MRI. EJR 2020; 131:109251.
Fliedner FP, Engel TB, El-Ali HH, Hansen AE, Kjaer A. Diffusion weighted magnetic resonance imaging (DW-MRI) as a non-invasive, tissue cellularity marker to monitor cancer treatment response. BMC cancer 2020; 20:1–9.
Nakamizo A, Inamura T, Yamaguchi S, Inoha S, Amano T, Ikezaki K, et al. Diffusion-weighted imaging predicts postoperative persistence in meningioma patients with peritumoural abnormalities on magnetic resonance imaging. J Clin Neurosci 2003; 10:589–593.
Santelli L, Ramondo G, Della Puppa A, Ermani M, Scienza R, d’Avella D, et al. Diffusion-weighted imaging does not predict histological grading in meningiomas. Acta Neurochir 2010; 152:1315–9; discussion 1319.
Toh C-H, Castillo M, Wong A-C, Wei K-C, Wong H-F, Ng S-H, et al. Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging. AJNR 2008; 29:1630–1635.
Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging 2012; 39:1409–1415.
Mahase SS, Roth O’Brien DA, Ramakrishna R, Stieg PE, Knisely JPS, Ivanidze JD, Pannullo, et al. [68Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neurooncol. Adv 2021; 3:vdab012.
Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 2021; 23:1821–1834.
Grueneisen J, Schaarschmidt BM, Heubner M, Aktas B, Kinner S, Forsting M, et al. Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur J Nucl Med Mol Imaging 2015; 42:1814–1824.
Mukaka MM. A guide to appropriate use of correlation coefficient in medical research. Malawi Med. J 2012; 24:69–71.
Schaarschmidt BM, Buchbender C, Nensa F, Grueneien J, Gomez B, Köhler J, et al. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI. PLoS One 2015; 10:e0116277.
Tyng CJ, Guimarães MD, Bitencourt AGV, dos Santos LCM, Barbosa PNVP, Zurstrassen CE, et al. Correlation of the ADC values assessed by diffusion-weighted MRI and 18F–FDG PET/CT SUV in patients with lung cancer. Cancer Res 2018; 38:1–7.
Tollefsen SE, Jarmund AH, Ytterhus B, Salvesen O, Mjønes P, Torp SH, Somatostatin receptors in human meningiomas—clinicopathological aspects. Cancers (Basel) 2021; 13:5704.
Dijkstra B, Motekallemi A, Den Dunnen W, Jeltema J, van Dam G, Kruyt F, et al. SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery. Acta Neurochir 2018; 160:1539–1546.
Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET imaging in patients with meningioma—report of the RANO/PET group. Neuro. Oncol 2017; 19:1576–1587.
Bruckmann NM, Rischpler C, Kirchner J, Umutlu L, Herrmann K, Ingenwerth M, et al. Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid 68Ga-DOTATOC PET/MRI. EJR 2021; 137:109588.
Weber M, Kessler L, Schaarschmidt B, Fendler WP, Lahner H, Antoch G, et al. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer 2020; 20:1–12.
Adams LC, Bressem KK, Brangsch J, Reimann C, Nowak K, Brenner W, et al. Quantitative 3D assessment of 68Ga-DOTATOC PET/MRI with diffusion-weighted imaging to assess imaging markers for gastroenteropancreatic neuroendocrine tumors: preliminary results. JNM 2020; 61:1021–1027.
Weber M, Kessler L, Schaarschmidt B, Fendler WP, Lahner H, Antoch G, et al. Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. Nucl Med Commun 2020; 41:363–369.
Surov A, Meyer HJ, Wienke A. Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 1: ADCmean. Oncotarget 2017; 8:598–602.
Surov A, Gottschling S, Mawrin C, Prell J, Spielmann RP, Wienke A, et al. Diffusion-weighted imaging in meningioma: prediction of tumor grade and association with histopathological parameters. Transl Oncol 2015; 8:517–523.
Surov A, Ginat DT, Sanverdi E, Lim CT, Hakyemez B, Yogi A, et al. Use of diffusion weighted imaging in differentiating between malignant and benign meningiomas. a multicenter analysis. World Neurosurg 2016; 88:598–602.
Tang Y, Dundamadappa SK, Thangasamy S, Flood T, Moser R, Smith T, et al. Correlation of apparent diffusion coefficient with Ki-67 proliferation index in grading meningioma. AJR Am J Roentgenol 2014; 202:1303–1308.
Gu H, Zhang X, Di Russo P, Zhao X, T Xu., The current state of radiomics for meningiomas: promises and challenges. Front Oncol 5677; 10:36.
Sommerauer M, Burkhardt J-K, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro. Oncol 2016; 18:1021–1027.
Slot KM, Verbaan D, Buis DR, Schoonmade LJ, Berckel van BN, Vandertop WP. Prediction of meningioma WHO grade using pet findings: a systematic review and meta-analysis. J Neuroimaging 2021; 31:6–19.
Barresi V, Alafaci C, Salpietro F, Tuccari G. Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep 2008; 20:485–492.